Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tomaralimab, an antibody targeting TLR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Temelimab, an antibody targeting MS-associated Retrovirus Envelope Protein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rozibafusp, an antibody targeting ICOS.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pepinemab, an antibody targeting SEMA4D.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Olinvacimab, an antibody targeting VEGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nimacimab, an antibody targeting CNR1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Murlentamab, an antibody targeting AMHR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mitazalimab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lorukafusp, an antibody targeting Ganglioside GD2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lacutamab, an antibody targeting KIR3DL2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Frovocimab, an antibody targeting PCSK9.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dilpacimab, an antibody targeting DLL4 × VEGF-A.